

10/570229

IAP6 Rec'd PCT/PTO 28 FEB 2006

Atty. Docket No. PB60476USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Ronnie Maxwell LAWRENCE

International Application No.: PCT/EP2004/009819

International Filing Date: September 2, 2004

For: *PROCESS FOR THE PREPARATION OF (1S, 4R)-CIS-4-[2-AMINO-6-CHLORO-9H-PURIN-9-YL]-2-CYCLOPENTENE-1-METHANOL*

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the references are enclosed  
[ ] Copies of the references were submitted in parent application Serial No. \_\_\_\_\_.  
(37 CFR 1.98(d))  
[X] A copy of the International Search Report which issued on International Application No. PCT/EP2004/009819 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- [ ] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. [ ] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,  
whichever occurs first.

Express Mail Label No.: EV332131204US

Date of Mailing: 2/28/2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

  
\_\_\_\_\_  
Patty Wilson

10/570229

Atty. Docket No. PB60476USw

IAP6 Rec'd PCT/PTO 28 FEB 2006

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. [ ] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [ ] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

  
Karen L. Prus  
Attorney of Record  
Registration No. 39,337

Date: February 28, 2006  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-2192  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>		<b>INT'L FILING NO.</b>	PCT/EP2004/009819
		<b>INT'L FILING DATE</b>	September 2, 2004
		<b>APPLICANT</b>	Lawrence
		<b>GROUP</b>	10/570229
		<b>EXAMINER</b>	
		<b>ATTORNEY DOCKET NO.</b>	PB60476USw

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
1.	0325460	10/21/1992	EP			
2.	0434450	7/7/1999	EP			
3.	0628044	12/14/1994	EP			
4.	0741710	11/13/1996	EP			
5.	WO95/21161	8/10/1995	PCT			
6.	WO98/52949	11/26/1998	PCT			
7.	WO99/19327	4/22/1999	PCT			
8.	WO00/19327	4/6/2000	PCT			

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

9.	BERGE et al., Pharmaceutical Salts, J. of Pharm. Sci. 66(1):1-19 (1977).
10.	DALUGE et al., An Efficient, Scalable synthesis of the HIV Reverse Transcriptase Inhibitor Ziagen® (1592U89), Nucleosides, Nucleotides & Nucleic Acids 19:297-327 (2000).
11.	FLEISHER et al., Improved oral drug delivery: solubility limitations overcome by the use of prodrugs, Advanced Drug Delivery Reviews 19:115-130 (1996).
12.	HIGUCHI and STELLA, Pro-drugs as Novel Drug Delivery Systems, ACS Symposium Series 14, Amer. Chem. Soc., (Sept. 1974).
13.	LEGRAVEREND et al., Synthesis of a New Series of Purine Derivatives and their Anti-Cyclin-Dependent Kinase Activities, J. Heterocyclic Chem. 38:299-303 (2001).
14.	PEDERSON et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide, Diabetes 47:1253-1258 (1998).
15.	VINCE and HUA, Synthesis and Anti-HIV Activity of Carbocyclic 2',3'-Didehydro-2',3'-dideoxy 2,6-Disubstituted Purine Nucleosides, J. Med. Chem. 33:17-21 (1990).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.